Eagle Health Investments LP Takes $5.01 Million Position in Protagonist Therapeutics, Inc. $PTGX
Eagle Health Investments LP has acquired a new position in Protagonist Therapeutics, purchasing 57,300 shares valued at approximately $5.01 million. This investment constitutes about 1.1% of Eagle Health's total portfolio, while institutional investors collectively own 98.63% of Protagonist Therapeutics. Despite recent insider selling, analysts maintain a "Moderate Buy" rating for PTGX with an average target price of $113.69, following better-than-expected earnings due to strong revenue and EPS.
Wolfe Research initiates Protagonist Therapeutics stock with outperform rating By Investing.com
Wolfe Research has initiated coverage on Protagonist Therapeutics (NASDAQ: PTGX) with an outperform rating and a price target of $135, citing the company's strong early-stage pipeline and validated biology. The firm anticipates significant catalysts including clinical proof of concept for three wholly-owned assets by early 2027 and highlights potential milestone payments from partners Johnson & Johnson and Takeda. Other analysts from BMO Capital, Citizens, Jefferies, Truist Securities, and Clear Street have also expressed confidence in Protagonist Therapeutics, setting price targets between $116 and $137.
Wolfe Research initiates Protagonist Therapeutics stock with outperform rating
Wolfe Research initiated coverage of Protagonist Therapeutics (NASDAQ:PTGX) with an outperform rating and a $135 price target, citing the company's strong early-stage pipeline and focus on peptides. The firm anticipates a catalyst-rich period with clinical proof of concept expected for three wholly-owned assets by early 2027. Protagonist Therapeutics also benefits from significant royalty and milestone payments from partnerships with Johnson & Johnson and Takeda, with $475 million expected from Takeda this year alone.
A Look At Protagonist Therapeutics (PTGX) Valuation After First Quarter Earnings Swing To Profit
Protagonist Therapeutics (PTGX) has transitioned from a net loss to a net profit in the first quarter of 2026, reporting US$3.78 million in income. Despite recent share price fluctuations, the stock has seen a significant 292.25% return over three years. While its current price-to-book ratio screens as expensive compared to the broader US biotech industry, a discounted cash flow model suggests a much higher fair value, raising questions about market caution regarding its pipeline and future cash flows.
Protagonist Therapeutics (PTGX) soars 4.7%: Is further upside left in the stock?
Protagonist Therapeutics (PTGX) saw its stock price increase by 4.7% recently. The article title asks whether the stock has potential for further gains, suggesting investor interest in its future performance.
This Just In: Analysts Are Boosting Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Outlook for This Year
Analysts have significantly upgraded their statutory forecasts for Protagonist Therapeutics, Inc. (NASDAQ:PTGX) for the current year, particularly increasing revenue estimates and forecasting a profit of US$3.72 per share. Despite the improved earnings outlook, the consensus price target remains unchanged at US$117. The company is expected to experience accelerated revenue growth of 12x higher than its historical 40% per annum over the past five years, outpacing the industry average of 22% annually.
AIHC Capital Management Ltd Buys New Shares in Protagonist Therapeutics, Inc. $PTGX
AIHC Capital Management Ltd has acquired a new stake of 189,823 shares in Protagonist Therapeutics (NASDAQ:PTGX) for approximately $16.6 million, making it their second-largest holding. This comes as Protagonist Therapeutics reported strong Q1 earnings, beating analyst expectations for both EPS and revenue, though the company has also seen recent insider stock sales worth millions. Analysts maintain a "Moderate Buy" rating with a consensus price target of $113.69 despite the insider activity.
Protagonist Therapeutics CEO Dinesh V. Patel sells $7.5m after option exercise
Dinesh V. Patel, CEO of Protagonist Therapeutics (NASDAQ:PTGX), sold common stock worth $7.5 million on May 12, 2026, after exercising options. The sale was executed under a 10b5-1 trading plan as PTGX stock neared its 52-week high, having returned 138% over the past year. Analysts from BMO Capital, Citizens, Jefferies, Truist, and Clear Street have all maintained positive ratings and raised price targets for Protagonist Therapeutics, citing strong commercial launches, anticipated approvals, and the successful validation of its peptide platform with Icotyde.
(SEC Amendment) Protagonist Therapeutics(PTGX.US) Officer Sells US$7.51 Million in Common Stock
This article reports on an SEC amendment stating that an officer of Protagonist Therapeutics (PTGX.US) sold common stock valued at $7.51 million. The transaction highlights significant insider activity for the company.
PTGX (NASDAQ: PTGX) CEO sells 75K shares under 10b5-1 trading plan
Protagonist Therapeutics President and CEO Dinesh V. Patel exercised stock options for 75,000 shares at $21.58 each and subsequently sold these 75,000 shares in open-market trades at a weighted average price of $100.12 per share. These transactions, which occurred on May 12, 2026, were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on January 30, 2026. Following the sales, Patel directly holds 523,478 common shares of PTGX.
Protagonist Therapeutics CEO Dinesh V. Patel sells $7.5m in shares
Protagonist Therapeutics CEO Dinesh V. Patel sold 75,000 shares of the company's common stock for $7.5 million after exercising an equal number of stock options. This transaction follows a significant 121% return for the stock over the past year, with the shares trading near their 52-week high. The sale and subsequent holding adjustments come amidst positive analyst sentiment driven by promising commercial launches and anticipated approvals for the company's treatments.
75,000-share sale notice filed by PTGX insider (NASDAQ: PTGX)
An insider at Protagonist Therapeutics (NASDAQ: PTGX) has filed a Form 144 notice to sell 75,000 shares of common stock on May 12, 2026. This sale is connected to an option exercise set to occur on the same date and will be for cash proceeds. The filing also disclosed previous sales of 54,641 shares by Dinesh Patel on March 25, 2026.
Protagonist Therapeutics (NASDAQ: PTGX) CEO sells 75,000 shares after exercising options
Dinesh V. Patel, President and CEO of Protagonist Therapeutics (NASDAQ: PTGX), exercised stock options for 75,000 shares at $21.58 each and subsequently sold all 75,000 shares in open-market transactions for a weighted average price of $100.12. Following these transactions, Patel directly holds 523,478 common shares. The options were fully vested and are set to expire on October 11, 2026, indicating a routine exercise-and-sell transaction.
Protagonist Therapeutics President, CEO Sold Shares Worth Over $7.5M
Dinesh V. Patel, President and CEO of Protagonist Therapeutics (PTGX), sold common stock totaling $7,509,000. The shares were sold at a weighted average price of $100.12, ranging from $98.83 to $103.50, and he now directly owns 523,478 shares. This information is based on an SEC Form 4 filing.
State Street Holds 3.12M Protagonist Therapeutics Shares (PTGX)
State Street Corporation has reported a beneficial ownership of 3,116,804 shares in Protagonist Therapeutics Inc., constituting a 4.9% stake in the company. This disclosure was made via a Schedule 13G filing, indicating a passive investment intent. The filing details shared voting power of 2,956,605 shares and shared dispositive power of 3,116,804 shares, with several State Street entities listed as holders.
Insiders At Protagonist Therapeutics Sold US$11m In Stock, Alluding To Potential Weakness
Protagonist Therapeutics insiders recently sold US$11 million worth of stock, including CEO Dinesh Singh's significant sale. This activity, especially the large dollar amount and the timing relative to the company's market cap, suggests a potential lack of confidence from those with the most insight into the company's future. While insider selling doesn't always predict a downturn, large-scale unfollowing of their own stock often warrants investor attention.
Protagonist Therapeutics Insider Sold Shares Worth $5,918,880, According to a Recent SEC Filing
An insider at Protagonist Therapeutics sold shares worth $5,918,880. This transaction was disclosed in a recent SEC filing. The article provides details on the insider sale but does not disclose who the insider was.
Protagonist Therapeutics(PTGX.US) Director Sells US$5.92 Million in Common Stock
A director of Protagonist Therapeutics (PTGX.US) recently sold 288,382 shares of common stock for a total of $5.92 million. This transaction occurred on May 9, 2026, at an average price of $20.53 per share, as disclosed in a Form 4 filing with the SEC.
[Form 4] Protagonist Therapeutics, Inc Insider Trading Activity
Protagonist Therapeutics director Bryan Giraudo reported exercising stock options and selling shares of common stock. On May 7, he exercised options for 36,000 shares and sold 36,000 directly held shares for approximately $100.14 per share, while The Bryan & Courtney Giraudo Trust sold an additional 12,000 shares. On May 8, Giraudo sold 5,130 directly held shares and the trust sold another 6,000 shares, after which Giraudo holds 12,695 shares directly and the trust no longer holds shares from these reported transactions.
Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) Director Sells 36,000 Shares of Stock
Protagonist Therapeutics (NASDAQ:PTGX) Director Bryan Giraudo sold 36,000 shares of the company's stock for over $3.61 million, significantly reducing his ownership. This sale occurred while the stock traded near its 52-week high, and the company recently beat earnings expectations. Analysts generally maintain a "Moderate Buy" rating for PTGX.
Protagonist Therapeutics Director Sold Shares Worth Over $5.9M
Bryan Giraudo, a Director at Protagonist Therapeutics (PTGX), reported selling shares worth over $5.9 million on May 7-8, 2026. The average sale price was $100.14 per share. Following these transactions, Giraudo directly owns 12,695 shares and no longer has indirect ownership through a trust.
Protagonist Therapeutics director Giraudo sells $5.9m in shares
Protagonist Therapeutics director Bryan Giraudo sold approximately $5.92 million worth of shares in early May, following the exercise of stock options. These transactions, occurring on May 7 and 8, 2026, involved both direct and indirect sales, with shares trading between $100.00 and $100.14. Despite the high stock price, which is up 129% over the past year, InvestingPro analysis suggests the shares are overvalued, while several analysts maintain positive outlooks on the company, citing strong commercial momentum and promising drug developments like Icotyde.
State of New Jersey Common Pension Fund D Sells 20,969 Shares of Protagonist Therapeutics, Inc. $PTGX
State of New Jersey Common Pension Fund D reduced its stake in Protagonist Therapeutics, Inc. by 55.2% in the fourth quarter, selling 20,969 shares and retaining 16,987 shares valued at $1.48 million. This comes amidst significant insider selling, including sales by CEO Dinesh V. Patel and Director Lewis T. Williams. Despite the institutional selling, PTGX has strong analyst support with a "Moderate Buy" consensus and a $113.69 price target, alongside positive quarterly results exceeding revenue and EPS estimates.
Does Milestone-Driven Profit Shift the Bull Case For Protagonist Therapeutics’ New Model (PTGX)?
Protagonist Therapeutics (PTGX) reported an unexpected profit in Q1 2026 due to a US$50 million FDA milestone payment for ICOTYDE and a US$200 million payment from restructuring its rusfertide collaboration. This shifts the company's business model towards milestone- and royalty-based revenues, supported by significant liquidity of US$620.3 million. Investors now need to evaluate Protagonist as a platform anchored by partnerships, with the FDA's rusfertide decision being a key near-term catalyst.
Protagonist Therapeutics price target raised to $130 from $125 at Citi
Citi has increased its price target for Protagonist Therapeutics (PTGX) to $130 from $125, maintaining a Buy rating on the shares. This adjustment follows the company's "transformative" Q1 report, highlighted by the approval of Icotyde. Other firms like Citizens and Goldman Sachs have also raised their price targets for Protagonist Therapeutics.
Nan Fung Trinity HK Ltd. Has $15.78 Million Stock Position in Protagonist Therapeutics, Inc. $PTGX
Nan Fung Trinity HK Ltd. increased its stake in Protagonist Therapeutics (NASDAQ:PTGX) by 24.7% in the fourth quarter, bringing its total holdings to 180,670 shares valued at $15.78 million. Analysts have a "Moderate Buy" consensus rating for PTGX with an average price target of $113.69, following the company's strong Q4 earnings report which significantly beat revenue and EPS estimates. Despite the positive outlook from analysts and strong financial performance, company insiders have recently sold a substantial number of shares.
Protagonist Therapeutics (NASDAQ:PTGX) Rating Increased to Strong-Buy at Wall Street Zen
Wall Street Zen has upgraded Protagonist Therapeutics (NASDAQ: PTGX) from "hold" to "strong-buy," contributing to a positive analyst sentiment. Several other firms have also raised their price targets for PTGX. The company recently reported strong quarterly earnings, beating expectations with an EPS of $0.05 and revenue of $56.37 million.
Insider sales at PTGX (NASDAQ: PTGX) — 48,000 shares disclosed (05/07/2026)
Bryan M. Giraudo and Bryan M. & Courtney L. Giraudo reported the disposition of 48,000 shares of Protagonist Therapeutics (PTGX) common stock in a Form 144 filing on May 7, 2026. Bryan M. Giraudo sold 36,000 shares for $3,604,968.00, and Bryan M. & Courtney L. Giraudo sold 12,000 shares for $1,200,873.60. The filing also detailed prior compensation issuances of 6,000 shares in December 2019 and 5,130 shares in January 2026.
PTGX PE Ratio & Valuation, Is PTGX Overvalued
Protagonist Therapeutics Inc (PTGX) is currently considered to be in the "Fair zone" with a forward P/S ratio of 40.89. Its fair price is estimated to be between $71.81 and $176.43 using a relative valuation method. The company's P/B ratio and FCF yield are higher and lower, respectively, than their historical averages, and its P/S ratio is above the industry average but supported by strong revenue growth.
Protagonist Therapeutics Q1 Profit Challenges Trailing Loss Narrative For PTGX Investors
Protagonist Therapeutics (PTGX) reported Q1 2026 revenue of US$56.4 million, with a net income of US$3.8 million and Basic EPS of US$0.06, contrasting with a trailing 12-month net loss of US$114.7 million. While the company's trailing 12-month revenue growth is 27.6%, quarterly revenue and profitability have been uneven. The stock currently trades at US$103.97, significantly below its DCF fair value of US$379.45, presenting a tension between valuation caution and potential upside despite higher P/B ratios compared to the industry.
Protagonist Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Protagonist Therapeutics (NASDAQ:PTGX) surpassed first-quarter earnings expectations, reporting revenues of US$56m and a statutory profit of US$0.05 per share, significantly outperforming analyst forecasts for a loss. Following these strong results, analysts have substantially increased their 2026 revenue and earnings per share estimates, now expecting US$553.8m in revenue and US$4.54 EPS. Despite these upgrades, the consensus price target remains constant at US$116, suggesting that while sentiment has improved, the long-term valuation has not been significantly altered.
[144] Protagonist Therapeutics, Inc SEC Filing
This article details a Form 144 SEC filing by Protagonist Therapeutics, Inc. (PTGX) on May 7, 2026. The filing indicates a proposed sale of 36,000 shares of common stock acquired through a stock option exercise, with an aggregate market value of $3,604,968.00, handled by Morgan Stanley Smith Barney LLC.
PTGX (NASDAQ) Form 144: Insider notice to sell 12,000 shares
Protagonist Therapeutics, Inc. (PTGX) has filed a Form 144 notice, indicating a proposed sale of 12,000 shares of common stock. These shares originate from two compensation-related grants in 2018 and 2019, with a reported value of $1,200,873.60. The filing, dated May 7, 2026, serves as a notice of intent to sell restricted securities and does not confirm that the sales have already occurred.
Goldman Sachs Maintains Protagonist Therapeutics(PTGX.US) With Hold Rating, Raises Target Price to $110
Goldman Sachs has reiterated its Hold rating on Protagonist Therapeutics (PTGX.US) and increased the price target from $99 to $110. This adjustment reflects the firm's updated outlook on the company's valuation.
Protagonist Therapeutics Q1 Profit Challenges Trailing Loss Narrative For PTGX Investors
Protagonist Therapeutics (PTGX) reported a Q1 2026 profit with revenue of US$56.4 million and a net income of US$3.8 million, despite still showing a trailing 12-month net loss of US$114.7 million. This quarterly profit provides some validation for bullish investors highlighting the company's loss reduction trend. The stock's current valuation, with a significant discount to its DCF fair value but a high P/B ratio compared to the industry, presents conflicting signals for investors.
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $137.00
Citizens Jmp has increased its price target for Protagonist Therapeutics (NASDAQ:PTGX) to $137.00, indicating a potential upside of 34% from its previous close, contributing to a "Moderate Buy" consensus rating from analysts. This upgrade comes despite the company missing its recent quarterly earnings and revenue estimates. Notably, there has been significant insider selling of company stock amounting to over $15 million in the last 90 days, while institutional ownership remains high at 98.63%.
Vanguard Group Inc. Purchases 1,156,461 Shares of Protagonist Therapeutics, Inc. $PTGX
Vanguard Group Inc. significantly increased its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 27.2% in the fourth quarter, acquiring an additional 1,156,461 shares. Despite some institutional selling, institutional ownership remains very high at 98.63%, and analysts maintain a "Moderate Buy" rating with a consensus target price of $108.15, even after the company reported a mixed earnings miss. Insider selling has also occurred, with key executives reducing their holdings in the company.
Citizens JMP Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $137
Citizens JMP has reiterated its Buy rating on Protagonist Therapeutics (PTGX.US) and increased its price target to $137. This indicates a positive outlook from the firm regarding the biopharmaceutical company's future performance and potential stock growth.
Citizens raises Protagonist Therapeutics stock price target on platform validation
Citizens increased its price target for Protagonist Therapeutics (NASDAQ:PTGX) to $137 from $120, maintaining a Market Outperform rating, due to the validation of its peptide platform through ICOTYDE's approval and strong execution of partnered programs. While Protagonist is projected to have significant cash reserves and future earnings, InvestingPro indicates the stock may be overvalued relative to its fair value. Upcoming catalysts include potential Rusfertide approval in Q3 2026 and Phase 1 data for PN-881 and PN-47.
Protagonist Therapeutics: Q1 Earnings Snapshot
Protagonist Therapeutics Inc. (PTGX) reported a first-quarter profit of $3.8 million, or 5 cents per share, significantly exceeding Wall Street's expectations for a loss. The biopharmaceutical company, based in Newark, California, also posted revenues of $56.4 million for the period. These results were generated using data from Zacks Investment Research.
Protagonist Therapeutics: Q1 Earnings Snapshot
Protagonist Therapeutics Inc. (PTGX) reported a first-quarter profit of $3.8 million, or 5 cents per share, significantly surpassing Wall Street's expectations for a loss of 65 cents per share. The biopharmaceutical company also posted revenue of $56.4 million for the period. These results were generated using data from Zacks Investment Research.
Protagonist Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Protagonist Therapeutics Inc has released its earnings summary for the quarter that ended on March 31. The report contains financial results for the specified period.
A Look At Protagonist Therapeutics (PTGX) Valuation After ICOTYDE Approval And Rusfertide Priority Review
Protagonist Therapeutics (PTGX) is attracting attention following the FDA approval of ICOTYDE and Priority Review for rusfertide, along with significant payments from a Takeda opt-out. Despite recent stock pullbacks, the company shows strong long-term share price returns. Simply Wall St's DCF model suggests the stock is significantly undervalued at $373.32 per share compared to its current price, while analysts have a more conservative average target of $113.33.
Milestones and Takeda opt-out reshape Protagonist (NASDAQ: PTGX) outlook
Protagonist Therapeutics reported a profitable first quarter of 2026, driven by a $50 million milestone payment for FDA approval of ICOTYDE and a strong cash position of $620.3 million. The company expects further revenue growth from its collaboration with Johnson & Johnson for ICOTYDE and from an amended agreement with Takeda for rusfertide, where Protagonist exercised its opt-out right, triggering a $200 million payment and future royalties. Despite increased R&D and general administrative expenses, the company's financial outlook is reshaped by these strategic milestones and deal restructuring.
Protagonist Therapeutics (NASDAQ:PTGX) Posts Earnings Results, Beats Expectations By $0.70 EPS
Protagonist Therapeutics (NASDAQ:PTGX) announced earnings results, reporting an EPS of $0.05, significantly beating analyst consensus estimates of ($0.65) by $0.70. The company's revenue reached $56.37 million, far surpassing the $12.21 million expected. Despite the strong earnings beat, the company remains unprofitable with a negative net margin and negative return on equity, and recent insider selling has been noted.
Protagonist Therapeutics set to report as blockbuster bets grow
Protagonist Therapeutics (PTGX) is set to announce its first-quarter earnings, with investors keen to see the financial impact of its newly launched psoriasis drug, Icotyde, which Johnson & Johnson has hailed as a potential blockbuster. Analysts anticipate a loss of 49 cents per share on revenues of $12.2 million. The company's future hinges on Icotyde's commercial traction and potential changes to financial guidance, especially following the FDA approval and significant milestone payment received.
Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update
Protagonist Therapeutics reported significant achievements in Q1 2026, including FDA approval of ICOTYDE™ and Priority Review for rusfertide. The company also exercised its rusfertide opt-out right from the Takeda collaboration, triggering a $200 million payment and increasing future royalty potential. These developments, along with advanced pipeline assets and a strong cash position, are expected to provide cash runway through at least 2028.
Protagonist (NASDAQ: PTGX) posts Q1 profit amid ICOTYDE approval and $200M rusfertide opt-out
Protagonist Therapeutics (PTGX) reported a profitable first quarter in 2026, transitioning from a net loss to a net income of $3.8 million, driven by a significant increase in license and collaboration revenue to $56.4 million. This financial turnaround was bolstered by the FDA approval of ICOTYDE for plaque psoriasis, triggering a $50 million milestone payment, and the strategic opt-out from a rusfertide partnership with Takeda, which unlocked an immediate $200 million payment and future milestone and royalty potential. The company also maintains a strong balance sheet with $620 million in cash, expected to fund operations through at least 2028.
Protagonist Therapeutics set to report as blockbuster bets grow
Protagonist Therapeutics is set to release its first-quarter earnings, with investors keen to assess the initial financial impact of its newly launched psoriasis drug, Icotyde, which Johnson & Johnson executives believe could be a blockbuster. Analysts are watching for updated financial guidance, commentary on Icotyde's early commercial success, potential royalty revenues, and the company's plans for cash deployment and pipeline expansion. The earnings report comes at a crucial time as Icotyde's FDA approval has significantly altered Protagonist's investment narrative.
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Rating of "Moderate Buy" from Analysts
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) has received an average "Moderate Buy" rating from fifteen analysts, with a consensus one-year price target of $108.15. Despite recent analyst upgrades to price targets, the company missed Q1 earnings and revenue expectations. Institutional ownership is high at 98.63%, while insiders have sold a significant amount of shares recently.
